BioSyent’s businesses collectively delivered 23% revenue growth in 2025 while maintaining a 21% net income after tax (NIAT) margin on a consolidated basis.
BioSyent is proudly Canadian, listed on the TSX Venture stock exchange, with an all-Canadian team of employees who are dedicated to enhancing Canadian healthcare and work to find, develop and make available innovative medicines for Canadian patients and their healthcare professionals. Our products support many thousands of Canadians each year.
